Anti-epileptogenic Clinical Trial Designs in Epilepsy: Issues and Options

Neurotherapeutics

Volumn 11, Issue 2, 2014, Pages 401-411

  Schmidt, Dieter ^a   Friedman, Daniel ^b   Dichter, Marc A ^c  

^a Epilepsy Research Group   (Germany)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HUP   (United States)

Author keywords

Anti epileptogenic drugs; Antiepileptogenic drug trial design; Disease modification; Disease modifying drug trial design; Disease reversal; Disease reversing drug trial design; Epilepsy; Feasibility of trial design; Human biomarkers; Novel epilepsy trial design

Indexed keywords

ANTICONVULSIVE AGENT;

CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DRUG DESIGN; EPILEPSY; EPILEPTOGENESIS; FEASIBILITY STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STUDY DESIGN; TREATMENT DURATION; ANIMAL; DRUG DEVELOPMENT;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; EPILEPSY; HUMANS;

EID: 84899153469     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0252-z     Document Type: Review

References (68)

1. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006;129: 617-624.
2. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78: 1548-1554.
3. Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52: 657-678.
4. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011;10: 173-186.
5. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010;62: 668-700.
6. Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12: 757-776.
7. Mani R, Pollard J, Dichter MA. Human clinical trails in antiepileptogenesis. Neurosci Lett 2011;497: 251-256.
8. Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 2009;50: 10-13.
9. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9: 68-82.
10. Friedman D, French JA. Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions. Lancet Neurol 2012;11: 827-834.
11. French JA, White HS, Klitgaard H, Holmes GL, Privitera MD, Cole AJ, et al. Development of new treatment approaches for epilepsy: Unmet needs and opportunities. Epilepsia 2013;54: 3-12.
12. Dichter MA, Temkin N. Management of patients at high risk for seizures and epilepsy after traumatic brain injury and other risks (the Risk of Epilepsy Development (RED) syndrome). In: Shorvon S, Perucca E, Engel J, Jr (eds) Treatment of epilepsy. 3rd ed. Oxford, John Wiley, 2009; 249-258.
13. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001;42: 515-524.
14. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323: 497-502.
15. Temkin NR, Dikmen SS, Anderson GD, Wilensky AJ, Holmes MD, Cohen W, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999;91: 593-600.
16. Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991;265: 1271-1277.
17. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord 2012;14: 105-113.
18. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA 2006;296: 1731-1732.
19. Pitkänen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013;54: 35-43.
20. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40: 2244-2250.
21. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J-P, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 2010;11: 38-45.
22. D'Ambrosio R, Fairbanks JP, Fender JS, Born DE, Doyle DL, Miller JW. Post-traumatic epilepsy following fluid percussion injury in the rat. Brain 2004;127: 304-314.
23. McIntosh TK, Vink R, Noble L, Yamakami I, Fernyak S, Soares H, et al. Traumatic brain injury in the rat: Characterization of a lateral fluid-percussion model. Neuroscience 1989;28: 233-244.
24. Pitkänen A, Immonen RJ, Gröhn OH, Kharatishvili I. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009;50: 21-29.
25. Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury. Clinical Pharmacokinet 1998;35: 209-221.
26. Bruns J, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia 2003;44: 2-10.
27. Hesdorffer D, Logroscino G, Cascino G, Annegers J, Hauser W. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998;50: 735-741.
28. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004;35: 1769-1775.
29. Herman ST. Clinical trials for prevention of epileptogenesis. Epilepsy Res 2006;68: 35-38.
30. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002;58(8 Suppl. 5): S21-S26.
31. Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. Ann Neurol 1999;46: 45-50.
32. Annegers J, Hauser W, Beghi E, Nicolosi A, Kurland L. The risk of unprovoked seizures after encephalitis and meningitis. Neurology 1988;38: 1407.
33. Engel J. Biomarkers in epilepsy: introduction. Biomarkers 2011;5: 537-544.
34. Diaz-Arrastia R, Gong Y, Fair S, Scott KD, Garcia MC, Carlile MC, et al. Increased risk of late posttraumatic seizures associated with inheritance of APOE 4 Allele. Arch Neurol 2003;60: 818.
35. Gomes WA, Shinnar S. Prospects for imaging-related biomarkers of human epileptogenesis: a critical review. Biomark Med 2011;5: 599-606.
36. Mishra AM, Bai H, Gribizis A, Blumenfeld H. Neuroimaging biomarkers of epileptogenesis. Neurosci Lett 2011;497: 194-204.
37. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69: 89-95.
38. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361: 1268-1278.
39. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 314-319.
40. Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011;52: 619-626.
41. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs Effect of past treatment history. Neurology 2008;70: 54-65.
42. Sillanpää M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009;132: 989-998.
43. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51: 1069-1077.
44. Brooks-Kayal AR, Bath KG, Berg AT, Galanopoulou AS, Holmes GL, Jensen FE, et al. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 2013;54: 44-60.
45. Kanner AM. The treatment of depressive disorders in epilepsy: What all neurologists should know. Epilepsia 2013;54: 3-12.
46. Annegers JF, Hauser WA, Coan SP, Rocca WA. A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998;338: 20-24.
47. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998;44: 908-912.
48. Annegers JF, Grabow JD, Kurland LT, Laws ER. The incidence, causes, and secular trends of head trauma in Olmsted County, Minnesota, 1935-1974. Neurology 1980;30: 912.
49. Pitkänen A. Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia 2010;51(Suppl. 3): 2-17.
50. Annegers JF, Hauser WA, Shirts SB, Kurland LT. Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 1987;316: 493-498.
51. Maytal J, Shinnar S. Febrile status epilepticus. Pediatrics 1990;86: 611-616.
52. Shinnar S, Pellock JM, Berg AT, O'Dell C, Driscoll SM, Maytal J, et al. Short-term outcomes of children with febrile status epilepticus. Epilepsia 2001;42: 47-53.
53. Dubé CM, Ravizza T, Hamamura M, Zha Q, Keebaugh A, Fok K, et al. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010;30: 7484-7494.
54. Shinnar S, Bello JA, Chan S, Hesdorffer DC, Lewis DV, MacFall J, et al. MRI abnormalities following febrile status epilepticus in children The FEBSTAT study. Neurology 2012;79: 871-877.
55. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, et al. Stroke incidence among white, black, and hispanic residents of an urban community the Northern Manhattan Stroke Study. Am J Epidemiol 1998;147: 259-268.
56. Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Coté R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000;57: 1617.
57. Lossius MI, Rønning OM, Slapø GD, Mowinckel P, Gjerstad L. Poststroke epilepsy: occurrence and predictors-a long-term prospective controlled study (Akershus Stroke Study). Epilepsia 2005;46: 1246-1251.
58. Holden KR, Mellits ED, Freeman JM. Neonatal seizures I. Correlation of prenatal and perinatal events with outcomes. Pediatrics 1982;70: 165-176.
59. Legido A, Clancy RR, Berman PH. Neurologic outcome after electroencephalographically proven neonatal seizures. Pediatrics 1991;88: 583-596.
60. Ortibus E, Sum J, Hahn J. Predictive value of EEG for outcome and epilepsy following neonatal seizures. Electroencephalogr Clin Neurophysiol 1996;98: 175-185.
61. Saliba RM, Annegers JF, Waller DK, Tyson JE, Mizrahi EM. Incidence of neonatal seizures in Harris County, Texas, 1992-1994. Am J Epidemiol 1999;150: 763-769.
62. Mizrahi EM, Clancy RR. Neonatal seizures: Early-onset seizure syndromes and their consequences for development. Ment Retard Dev Disabil Res Rev 2000;6: 229-241.
63. Beghi E, Nicolosi A, Kurland LT, Mulder DW, Hauser WA, Shuster L. Encephalitis and aseptic meningitis, Olmsted County, Minnesota, 1950-1981: I. Epidemiology. Ann Neurol 1984;16: 283-294.
64. Wiederholt W, Gomez MR, Kurland LT. Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982. Neurology 1985;35: 600.
65. Webb D, Fryer A, Osborne J. On the incidence of fits and mental retardation in tuberous sclerosis. J Med Genet 1991;28: 395-397.
66. Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 1996;38: 146-155.
67. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008;63: 444-453.
68. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010;51: 1236-1241.